when was semaglutide approved A big win for Wegovy: Weight loss drug first in history to gain FDA approval for reducing heart risks FDA has approved a new,

Tirzepatide (Mounjaro, Zepbound) is a related but distinct dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist

B.SurP.EstepK.et al (2017)

Some online retailers claim they have the medication for sale, though

The low discontinuation rate, combined with significant weight loss and metabolic benefits, supports the conclusion that semaglutide maintains a favorable benefit-risk profile for most users under appropriate medical supervision

PubMed laboratory research record [PMID: 21228558] PubMed record related to this compound for laboratory literature review

Glucagon-like peptide-1 receptor agonists (also known as GLP-1 medications) get their name from a natural hormone found in the body